The Complaint alleges that defendants misled investors and/or failed to disclose that:
- the preclinical data submitted in support of FTX-6058 (a prospective drug for the potential treatment of sickle-cell disease) showed safety concerns regarding potential hematological malignancies;
- the foregoing safety concerns increased the likelihood that the U.S. Food and Drug Administration (“FDA”) would place a clinical hold on preclinical studies of FTX-6058;
- accordingly, the Company had overstated FTX 6058’s clinical and/or commercial prospects; and
- as a result, the Company’s public statements were materially false and misleading at all relevant times.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.